Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study

Author:

Elliott Jessie A.1,Klevebro Fredrik2,Mantziari Styliani3,Markar Sheraz R.45,Goense Lucas6,Johar Asif5,Lagergren Pernilla57,Zaninotto Giovanni7,van Hillegersberg Richard6,van Berge Henegouwen Mark I.89,Schäfer Markus3,Nilsson Magnus2,Hanna George B.7,Reynolds John V.1,

Affiliation:

1. Trinity St. James’s Cancer Institute, Trinity College Dublin, and St. James’s Hospital, Dublin, Ireland

2. CLINTEC, Karolinska Institutet and Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden

3. Lausanne University Hospital CHUV and University of Lausanne UNIL, Switzerland

4. Surgical Interventional Trials Unit, Nuffield Department of Surgery, University of Oxford, Oxford, United Kingdom

5. Karolinska Institutet, Department of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden

6. Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

7. Department of Surgery and Cancer, Imperial College London, St. Mary’s Hospital, London, United Kingdom

8. Department of Surgery, University of Amsterdam, Amsterdam, the Netherlands

9. Cancer Center Amsterdam, Amsterdam, the Netherlands

Abstract

Objective: This study aimed to compare clinicopathologic, oncologic and health-related quality of life (HRQL) outcomes following neoadjuvant chemoradiation (nCRT) and chemotherapy (nCT) in the ENSURE international multicenter study. Background Summary Data: nCT and nCRT are the standard of care for locally advanced esophageal cancer (LAEC) treated with curative intent. However, no published randomized controlled trial to date has demonstrated superiority of either approach. Methods: ENSURE is an international multicenter study of consecutive patients undergoing surgery for LAEC (2009-2015) across 20 high-volume centers (NCT03461341). The primary outcome measure was overall survival (OS), secondary outcomes included histopathologic response, recurrence pattern, oncologic outcome, and HRQL in survivorship. Results: 2,211 patients were studied (48% nCT, 52% nCRT). pCR was observed in 4.9% and 14.7% (P<0.001), with R0 in 78.2% and 94.2% (P<0.001) post nCT and nCRT, respectively. Postoperative morbidity was equivalent, but in-hospital mortality was independently increased (HR 2.73, 95%CI 1.43-5.21, P=0.002) following nCRT versus nCT. Probability of local recurrence was reduced (OR 0.71, 956% CI 0.54-0.93, P=0.012), and distant recurrence free survival time reduced (HR 1.18, 95% CI 1.02-1.37, P=0.023) after nCRT versus nCT, with no difference in OS among all patients (HR 1.10, 95% CI 0.98-1.25, P=0.113). On subgroup analysis, patients who underwent R0 resection following nCT as compared with nCRT had improved OS (median 60.7, 95% CI 49.5-71.8 months, vs. 40.8, 95% CI 42.8-53.4, P<0.001). Conclusions: In this European multicenter study, nCRT compared with nCT was associated with reduced probability of local recurrence but reduced distant recurrence free survival for patients with LAEC, without differences in overall survival. These data support tailored patient-specific decision-making in the overall approach to achieving optimum outcomes in LAEC.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3